Hyperphosphatemia

Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation

Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants

Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia

A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Assessing Tenapanor as a Treatment of CF-related Constipation.

AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

Long-term Study in Chronic Kidney Disease (Extension From Study 14817)

Study in Chronic Kidney Disease (CKD) Not on Dialysis

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease

Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients

Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate

Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients

Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 At Fixed Doses in Patients with Hyperphosphatemia

Tenapanor in Synucleinopathy-Related Constipation

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients

A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis

Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone

BAY 77-1931 Long-term Extension From Phase II Study

A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers

An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females

DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis

A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

Bioequivalence Study of BAY77-1931 Granule

Fosrenol Post-marketing Surveillance in Japan

The Effect of Systemic Dietary Instruction on Management of Plasma Phosphorus Levels in Peritoneal Dialysis (PD) Patients

Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan

Fosrenol Post-marketing Surveillance for Hemodialysis in Japan